Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 18/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 14/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 14/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 14/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32667388 | 0.89 | CHRNA4 (0.42) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL32667582 | 0.85 | PAX8 (0.40) | HDAC2CHRNA4CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL32667354 | 0.84 | PAX8 (0.37) | HDAC2CHRNA4CHRNB2CHRNA3HDAC1 | |
| SCHEMBL32667349 | 0.84 | MAPK14 (0.43) | HDAC2HDAC1HTR3A | |
| SCHEMBL32667572 | 0.82 | PTGS1 (0.36) | HDAC2HDAC1HTR3A | |
| SCHEMBL32667721 | 0.82 | PTGS2 (0.36) | HDAC2HDAC1 | |
| SCHEMBL32667516 | 0.81 | HDAC2 (0.39) | HDAC2HDAC1 | |
| SCHEMBL32667380 | 0.80 | NAMPT (0.42) | HDAC2 | |
| SCHEMBL32667560 | 0.77 | PDE4B (0.40) | CHRNA4CHRNB2CHRNA3 | |
| SCHEMBL32667678 | 0.75 | PTGS1 (0.35) | HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | GLUETACS THERAPEUTICS SHANGHAI CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028326-A1 | COMPOUND BASED ON ISOINDOLINE-SUBSTITUTED GLUTARIMIDE BACKBONE AND USE THEREOF | CDR2, CYC1, CLN6 | HDAC2 2112/4885CHRNA4 170/4885CHRNB2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.